医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LEO Pharma Scientists Win Innovator of the Year 2019 Award from Innovation Fund Denmark

2019年02月02日 AM02:05
このエントリーをはてなブックマークに追加


 

BALLERUP, Denmark

LEO Pharma, a global leader in medical dermatology, today announced that two of the company’s scientists have been awarded Innovation Fund Denmark’s Innovator of the Year Award 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190201005407/en/

Focus for the Innovator of the Year Award 2019 is on ‘excellent and groundbreaking research which creates value for Denmark’ – based on the following assessments:

• The value the candidates have created for patients as well as business

• The candidates’ ability to translate excellent research knowledge into tangible solutions

Marianne Lind, Ph.d., Senior Scientist and Karsten Petersson, Ph.d., Director, both at LEO Pharma, received the Award for the development of Enstilar®, LEO Pharma’s foam spray for the treatment of plaque psoriasis.

Enstilar® was approved by the Danish Medicines Agency and launched in Denmark in 2016, and more than one million patients use the product today.

The Innovator of the Year Award 2019 was presented by Minister of Education and Research Tommy Ahlers at a ceremony in Copenhagen, together with the Innovation Fund’s vice-chairman, Anja Boisen. In addition to the Award, the winners receive DKK 100,000 each.

In his speech to the Awards winners Danish Minister of Education and Research Tommy Ahlers said, among other:

“The projects you have created are innovative and exciting. Your projects build upon world class research, and we need that. Your achievements make a difference to our society. You are an inspiration to others – use it to be role models for the next generation of researchers. Congratulations on your ability and willingness tocreate something new – and congratulations on the Awards.”

See the full press release in the attached document.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190201005407/en/

CONTACT

LEO Pharma A/S
Trine Juul Wengel, Global External Communications
tewdk@leo-pharma.com
Tel.:
+45 20732037

同じカテゴリーの記事 

  • 画期的な報告書により、高いニコチン消費量は健康問題の発生率を高めないことが証明される
  • 基于LC-Plasma的疫苗研究入选SCARDA项目
  • LC-Plasma-based Vaccine Research Selected for SCARDA Project
  • 一份具有里程碑意义的报告证明,大量使用尼古丁不会导致健康问题高发
  • Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)